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North CarolinaABSTRACT Given the difficulty in finding a cure for HIV/AIDS, a promising prevention strategy to reduce HIV transmission is to
directly block infection at the portal of entry. The recent Thai RV144 trial offered the first evidence that an antibody-based vaccine
may block heterosexual HIV transmission. Unfortunately, the underlying mechanism(s) for protection remain unclear. Here we
theoretically examine a hypothesis that builds on our recent laboratory observation: virus-specific antibodies (Ab) can trap indi-
vidual virions in cervicovaginal mucus (CVM), thereby reducing infection in vivo. Ab are known to have a weak—previously
considered inconsequential—binding affinity with the mucin fibers that constitute CVM. However, multiple Ab can bind to the
same virion at the same time, which markedly increases the overall Ab-mucin binding avidity, and creates an inheritable
virion-mucin affinity. Our model takes into account biologically relevant length and timescales, while incorporating known
HIV-Ab affinity and the respective diffusivities of viruses and Ab in semen and CVM. The model predicts that HIV-specific Ab
in CVM leads to rapid formation and persistence of an HIV concentration front near the semen/CVM interface, far from the
vaginal epithelium. Such an HIV concentration front minimizes the flux of HIV virions reaching target cells, and maximizes their
elimination upon drainage of genital secretions. The robustness of the result implies that even exceedingly weak Ab-mucin af-
finity can markedly reduce the flux of virions reaching target cells. Beyond this specific application, the model developed here is
adaptable to other pathogens, mucosal barriers, and geometries, as well as kinetic and diffusional effects, providing a tool for
hypothesis testing and producing quantitative insights into the dynamics of immune-mediated protection.INTRODUCTIONAntibodies (Ab) produced by our immune system can bind
specifically to foreign pathogens, facilitating numerous
mechanisms of immune protection against infections.
Although more Ab are secreted into mucus that coats
exposed organs than into blood and lymph (1), how Ab
mediate protection in cervicovaginal mucus (CVM) coating
the female reproductive tract remains insufficiently under-
stood (2,3). Virus-specific Ab molecules can accumulate
on the surface of virions and directly inhibit them from bind-
ing and infecting target cells, a process known as ‘‘neutrali-
zation’’. However, whereas previous animal studies showed
that topical Ab molecules offer robust protection against
vaginal infections (4,5), protection was also found with anti-
bodies and at vaginal antibody titers that are unlikely to
adequately neutralize (6,7). Ab can elicit other protective
functions, such as ingestion and destruction of the pathogens
(opsonization) or infected cells (using antibody-dependent
cellular cytotoxicity (ADCC)) by specialized immune cells,
as well as activation of a cascade of enzymes that lead to
direct lysis of the pathogen membrane (complement) (8).
However, healthy female genital secretions typically have
little complement activity and few—if any—active leuko-Submitted September 4, 2013, and accepted for publication February 21,
2014.
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in the vaginal flora (9–11). The aforementioned classical
mechanisms of immune protection, therefore, do not
adequately explain many instances of Ab-mediated protec-
tion found in the female reproductive tract, including
the landmark Thai RV144 HIV vaccine trial, the first HIV
vaccine to show significant protection in humans (12,13).
The RV144 vaccination regimen reduced the risk of HIV
acquisition by ~30% over 3 years despite inducing primarily
nonneutralizing Ab, and offering otherwise little to no pro-
tection against systemic progression of HIV infections in
vaccinated subjects infected with HIV (13).
The extremely promising yet puzzling findings of the
RV144 trial, along with similarly confounding observations
from different in vivo studies, compel the exploration of
additional mechanisms of immune protection at mucosal
surfaces. Recently, we began focusing on an alternative
mechanism of vaginal immunity, whereby an array of
virion-bound Ab collectively imparts to the individual
virion multiple weak Ab-mucin bonds, generating sufficient
avidity to slow-down or even immobilize individual virions
in mucus. We note that the coupling of weak Ab-mucin af-
finity to Ab-virion binding kinetics as a mechanism of
mucosal immunity has been previously explored but gener-
ally dismissed, in part because repeated efforts have gener-
ally failed to detect (i.e., high affinity) binding of individual
Ab to mucins (14–17). Olmsted et al. (14) and Saltzmanhttp://dx.doi.org/10.1016/j.bpj.2014.02.038
Modeling the IgG-Mucin Barrier to HIV 2029et al. (17) showed that both Immunoglobulin G and A (IgG
and IgA) antibodies exhibit rapid diffusion in human cervi-
cal mucus, and slowed only slightly (~5–20%) compared to
their diffusion in water, with no immobilized (strongly
bound) fraction detected. Because Ab are much smaller
than the mesh pores (14,18), any reduced mobility must
be due to very short-lived (<1 s) binding interactions with
the mucin mesh that are readily broken by thermal excita-
tion. Such low affinity of Ab molecules to mucins clearly
implies that a single virion-bound Ab cannot adequately
slow a virion. However, because many Ab molecules can
bind to an individual virion, the cumulative Ab-mucin affin-
ity can be inherited by the host virion, assuming that the
binding of IgG-Fab to virion does not interfere with the
overall IgG-mucin interactions. Based on this assumption,
virion diffusion may be increasingly hindered with each
additionally bound Ab (refer to Fig. 1 A). Although initially
postulated nearly 10 years ago (9) as of this writing, this hy-
pothesis was not substantiated experimentally until Wang
et al. (19) recently confirmed that Herpes simplex virus
serotype 1 (HSV-1) readily penetrated human CVM with
low or no detectable endogenous anti-HSV-1 IgG, and
became trapped in samples with modest (i.e., subneutraliz-
ing) levels of endogenous or exogenously-added anti-
HSV-1 IgG (19).
Furthermore, the IgG-mucin interactions appear to be
markedly influenced by N-glycans on IgG-Fc. A nonneutr-
alizing but binding IgG facilitated effective protection
against vaginal Herpes infection in mice; interestingly, the
protection was abolished when vaginal mucus was removed,
indicating that virus-specific IgG can indeed work in tandem
with mucus to reduce infection. We are now making similar
observations of IgG-induced trapping with a variety of
mucus secretions from different animal species against
different viruses, highly motile bacterial pathogens, and
synthetic nanoparticles (see Movie S1 and Movie S2 in
the Supporting Material). Because our experiments are
based on particle tracking of individual pathogens, we avoid
potential pitfalls observed previously by Pando et al. (20)A B
FIGURE 1 (A) Schematic depicting multiple HIV-bound IgG immobilizing H
matic of our model for diffusion of HIV from seminal secretions across a cerv
to the underlying vaginal epithelium. To reduce infection, IgG must bind to HIV
HIV virions successfully penetrate CVM and reach the vaginal epithelium. (C
various times postejaculation. To see this figure in color, go online.and ten Wolde and Tanase-Nicola (21), where fluores-
cence-recovery-after-photobleaching was used to infer
diffusion coefficients of tagged particles in the presence of
traps (where Ab-mucin binding events are the traps) can
lead to potentially inaccurate results.
These results raise the possibility that this tandem effect
of weak Ab-mucin affinity, coupled with rapid virion-bind-
ing kinetics of vaccine-elicited Ab, can hinder the diffusion
of HIV across CVM and limit the flux of virions reaching
target cells. It is important to note that HIV deposited in
the female reproductive tract can rapidly penetrate genital
secretions (22,23); thus, there is a very limited window of
opportunity for Ab to bind and accumulate on the virus sur-
face and hinder virions before they penetrate the CVM and
reach target cells in the submucosa (S. A. McKinley,
A. Chen, F. Shi, S. Wang, P. J. Mucha, M. G. Forest, and
S. K. Lai, unpublished). In addition, HIV virions are typi-
cally characterized by a sparse density of surface antigen
sites, making it even more difficult to achieve a sufficient
number of virion-bound Ab to hinder their diffusive trans-
port across the CVM.
To better understand the subtle yet potentially significant
interplay between these kinetic and diffusive processes
associated with CVM laden with IgG molecules that have
weak mucin affinities, the introduction of HIV-laden
semen, and the unfolding of events in vivo, we developed
a mathematical model to incorporate measured kinetic
and diffusion constants and parameterize the least-under-
stood rate constants (e.g., the putative weak Ab-mucin
affinity). This model allows us to simulate the transmission
of HIV in seminal secretions through Ab-laden CVM
just after sexual intercourse under physiologically relevant
conditions, with Ab concentration, Ab-antigen binding
kinetics, and Ab-mucin affinity as tunable model parame-
ters (Fig. 1 A). We can then use numerical simulations to
explore the impact of varying degrees of weak Ab-mucin
affinity on the expected potency of Ab-mediated protection
against vaginal HIV infection. We find that the coupling of
weak Ab-mucin affinity to Ab-HIV binding kinetics hasC
IV virions in CVM via multiple low-affinity IgG-mucin bonds. (B) Sche-
icovaginal mucus (CVM) layer supplemented with anti-HIV IgG en route
in sufficient quantities to neutralize or to trap the virions in mucus before
) Predicted concentration profiles of IgG in the semen and CVM layers at
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2030 Chen et al.two important consequences: 1. The interactions between
pathogen-bound Ab and mucins directly reduce the flux
of HIV reaching the vaginal epithelium. We can then pre-
dict the extent of flux reduction based on specified IgG-
mucin affinity, IgG concentration, IgG-antigen binding
affinity, and semen/CVM thicknesses. 2. There is a rapid
formation of a surprisingly highly localized concentration
of virions (a virion concentration front) near the semen/
CVM interface most distant from the epithelial cells. This
virion concentration front not only contributes to our calcu-
lated reduction in virion flux, but presumably can also facil-
itate rapid elimination of trapped virions by natural mucus
clearance mechanisms.MATERIALS AND METHODS
Modeling the physiology of HIV transmission in
the female reproductive tract
Typically, the vaginal epithelium is highly folded into collapsed rugae
coated with a layer of viscoelastic and adhesive CVM gel. During coitus,
the epithelium becomes somewhat stretched and exposed. For simplicity,
we thus model the vaginal epithelial surface as the inner surface of a simple
cylinder coated with a roughly d ¼ 50-mm-thick CVM layer containing
HIV-specific Ab (see Fig. 1 A). The thickness of the CVM coating is
estimated based on total volumes of mucus that can be collected in the
absence of coital stimulation, and assumed to be constant and uniform
(S. A. McKinley, A. Chen, F. Shi, S. Wang, P. J. Mucha, M. G. Forest,
and S. K. Lai, unpublished; (25,26)). After ejaculation, the seminal fluid
is assumed for simplicity to evenly overlay the CVM layer with a thickness
of ~200 mm (27), with virions uniformly dispersed within the seminal secre-
tions at a density of 2.8  105 virions/mL (28).
Once virions penetrate CVM and reach the epithelial lumen, virions
must still access target cells in the submucosa, and intact stratified vaginal
epithelia has long been believed to serve as a mechanical barrier excluding
virus access. Nevertheless, HIV virions have been observed to quickly
penetrate the superficial layers of the stratified epithelium in human cervi-
cal explants and the female rhesus macaque genital tract, thereby gaining
access to superficial Langerhans cells and CD4þ T cells (29,30). The
timescale required for successful cellular penetration of HIV may be
further reduced by any preexisting micro or macro lesions in the epithe-
lium as well as abrasions upon coital stirring (31,32). Thus, in the absence
of an established mathematical model that can accurately recapitulate HIV
penetration of the squamous epithelium, we chose virion passage through
the CVM layer as the timescale to evaluate Ab-mediated trapping of
virions, up to a maximum of 2 h. Similar assumptions were previously
made by Geonnotti and Katz (33) and Lai et al. (34) to model the efficacy
of microbicides against HIV and the role of the thickness of the microbi-
cide gel layer. Thermal degradation based on gp120 shedding (T1/2 ~ 30 h)
and thermal degradation from RNA polymerase decay (T1/2 ~ 40 h) are not
incorporated because of the substantial difference in the rate of these pro-
cesses from the timescale of interest (35).Accumulation of antibodies on HIV
The rates with which broadly neutralizing Ab, such as NIH45-46, accumu-
late on HIV virions are dependent on Ab-antigen affinity, the number of
available antigen sites, and the local antibody concentration. The binding
affinity for NIH45-46 to gp120 Env spikes of HIV virions is described pre-
viously in Scheid et al. (36). The number of Env spikes N* on individual
HIV virions are variable, and was estimated to follow a negative binomial
distribution with N* ¼ 145 7 (range 4–35) based on cryo-electron micro-Biophysical Journal 106(9) 2028–2036scopy of HIV virions (37). Each Env spike is composed of trimeric gp120
molecules that can be bound by up to three monoclonal IgGs without sig-
nificant steric obstruction in IgG binding. Ab bind and unbind to individual
sites at rates kon and koff, and the overall binding/unbinding rates are depen-
dent on the number of unoccupied binding sites (3N*  n) and the local
antibody concentration u(z,t). Denoting IgG concentration in CVM as
u(z,t), the viral load as a vector
~vðz; tÞ ¼ ðv0ðz; tÞ; v1ðz; tÞ;.; v3N ðz; tÞÞ;
with vn representing the concentration of virions with n Ab bound at (z,t),
we can estimate the rates with which IgG can accumulate on HIV virions
over t ε [0,T] up to maximum time T of 2 h (S. A. McKinley, A. Chen, F.





where (Ab) denotes an unbound Ab and (Ab)n Z (t) denotes a virion at Z(t)
with n bound antibodies.Diffusion of viruses, antibodies, and antibody-
virus complexes in CVM
Due to rapid diffusivity of protons, semen-mediated neutralization of CVM
is assumed to occur instantaneously, in good agreement with prior measure-
ments of vaginal pH during and after coitus (38,39). Thus, for HIV virions
without bound Ab, we adopted the measured diffusivity of individual HIV
virions in pH-neutralized CVM (22) as the virion diffusivity in CVM. This
diffusivity is only a fewfold reduced compared with the theoretical virion
diffusivity in water/buffer; we therefore assumed the same diffusivity value
for HIV virions in semen. We further assume coital stirring motion does not
influence the movement of virions into the epithelial layer, due to the visco-
elastic nature of CVM and semen.When mucus is sheared between two sur-
faces, adhesive contacts and entanglements between mucin fibers are drawn
apart and a slippage plane forms parallel to the two surfaces, which is re-
flected by the shear-thinning rheological profile of mucus (9,35). Thus,
although the viscous drag between the surfaces drops considerably,
enabling mucus to function as an effective lubricant, the gel layers adhering
to both surfaces remain unstirred even in the presence of vigorous shearing
actions from copulation. This suggests CVM and semen can be largely
modeled as immiscible layers over the timescale of the simulation, and vi-
ruses in semen are unlikely to be easily stirred into the mucus layer
adhering to the vaginal epithelium.
Our mathematical model describes the dynamics of male-to-female HIV
transmission from the instant semen is ejaculated into the vaginal lumen
(time t ¼ 0), tracking the diffusion of HIV virions from the semen layer
(d < z < L) into the CVM layer (0 < z < d) and finally to the epithelium
(z ¼ 0). (See Fig. 1 B for schematic; Table 1 lists the various input param-
eters.) The process continues for each virion for 2 h or until the virion rea-
ches the vaginal epithelium, whichever occurs first (see above for further
details). IgG is the predominant Ab subclass found in CVM (rather than
IgA) (40,41). The diffusion of IgG in mucus may be slowed by interactions
with mucins (9,42); fluorescence-recovery-after-photobleaching studies
showed that IgG is slowed only slightly (~5–20%) by low-affinity interac-
tions with mucins in midcycle human cervical mucus compared with its
diffusion in water, with no permanently bound fractions (14,17). Given
the far lower mucin content in semen, we assume the diffusivity of IgG
in semen is comparable with its diffusivity in water. Because of its rapid
diffusivity, we expect IgG to be uniformly distributed in CVM at t ¼ 0,
rapidly enter the semen layer when t > 0, and achieve a steady-state distri-
bution within minutes, with a slightly higher steady-state concentration in
CVM versus that in semen (Fig. 1 C).
To model whether weak affinity between each individual IgG with
mucins can facilitate HIV trapping when multiple IgG are bound to the
A B
TABLE 1 Parameters and values incorporated into the model
Parameter Symbol Value
HIV-1
Radius rHIV 50 nm
Diffusivity in semen Dv0 1.27 mm
2/s
Diffusivity in CVM Dvn a
nDv0
Viral load in semen 8.4  105 copies/ejaculate
Number of Env trimer spikes N* 145 7 (SD)
bnAb (IgG)
Ab-mucin affinity a Variable
Diffusivity in semen DAb 40 mm
2/s
Diffusivity in CVM aDAb Variable
Initial Ab concentration in
CVM (NIH45-46)
[NIH45-46] Variable
Ab-Env affinity (NIH45-46) kon, koff 4.26  104, 2.87  104
Vagina
Surface area of lumen SAvagina 145 cm
2
Volume of luminal CVM VCVM 750 mL
Thickness of CVM Layer HCVM 50 mm
Volume of semen Vsemen 3.0 mL
Thickness of semen layer Hsemen 200 mm
Modeling the IgG-Mucin Barrier to HIV 2031same virion (Fig. 1 A), we define a to be the ratio of the diffusivity of IgG in
mucus versus in water (¼ Dmucus/Dwater ~ 0.8–0.95). The quantity a is
therefore a phenomenological parameter that represents the fraction of
time that an IgG molecule can freely diffuse in the mucin network:
a ¼ 1 corresponds to no affinity; smaller a implies greater affinity; and
a ¼ 0 indicates permanent binding between an individual IgG molecule
and mucins. This parameter can be written directly in terms of Ab-mucin
binding kinetics. Let mD ¼ moff/mon denote the ratio of the Ab-mucin un-
binding and binding rates, respectively, and let [M] denote the effective
concentration of Ab binding sites that are available in the mucin network.
Then, by standard Markov chain kinetics, a ¼ 1/(1 þ [M]/mD). This
estimate is consistent with previous analyses (20,43). Assuming each
HIV-bound IgG binds and unbinds to the mucin mesh independently, we
can estimate the diffusivity of an HIV-IgG complex in terms of the number
n of IgG bound to the virion and a: an HIV virion is assumed to be mobile
during the an fraction of time that all of its n bound IgG molecules are not
bound to the mucin mesh, giving a time-averaged diffusivity Dvn ¼ anDv0.
See Table 2 for a definition of terms used in this article.C DRESULTS
Low-affinity IgG-mucin interactions alone can
effectively trap HIV in mucus
We have previously shown that HIV virions diffuse
readily in pH-neutralized CVM (mimicking semen-inducedTABLE 2 Abbreviations used in the text
Abbreviation Name/explanation
Ab Antibody
ADCC Antibody-dependent cellular cytotoxicity
CVM Cervicovaginal mucus
HSV Herpes simplex virus
HIV Human immunodeficiency virus
HPV Human papillomavirus
IgA, IgG Immunoglobulin A, Immunoglobulin G (two common
classes of Ab molecules)
IC50, IC80 Ab concentrations to inhibit viral infectivity by 50 and 80%,
respectivelyneutralization of acidic CVM), and a substantial fraction of
HIV virions can penetrate CVM and reach the vaginal
epithelium within minutes (22). We now examine whether
Ab can accumulate on HIV in sufficient quantities within
this narrow time window to retard virus diffusion, using
the formula for Dvn, and thereby reduce the flux of virions
reaching target cells. We choose NIH45-46, a recently
discovered Ab from the lab of Diskin et al. (44) that targets
the gp120 molecules present on the envelope (Env) spikes of
HIV, because it has the following characteristics: 1. Very
high affinity to Env; 2. High neutralization potency (i.e.,
low IC50 and IC80 values (see Table 1)); and 3. Wide breadth
of neutralization against diverse HIV strains (36,44). At an
initial concentration of 5 mg/mL in CVM, which would
represent ~1% of all secreted IgG found in CVM, NIH45-
46 quickly accumulates on the surface of HIV; within 10
and 30 min, respectively, we estimate an average HIV virion
is bound by ~10 and 20 NIH45-46, respectively (Fig. 2, A
and B).
To illustrate the impact of the weak IgG-mucin interac-
tions, we directly compare selected virion diffusion paths
without IgG-mucin interactions (a ¼ 1) versus paths under
identical Brownian realizations, where each bound NIH45-
46 interacts with mucins ~10% of the time (i.e., a ¼ 0.9)
(Fig. 2, C and D). Virions initially located at a greater dis-
tance away from the semen/CVM interface appear to
become trapped near the interface (Fig. 2 C). In contrast, vi-
rions that start off near the semen/CVM interface are able to
diffuse some distance into the CVM layer before becomingFIGURE 2 Dynamics of HIV virions diffusing across CVM supple-
mented with NIH45-46. (A and B) The kinetics of accumulation of
NIH45-46 IgG on example HIV virions, and their spatial location over
time (C and D). Virion paths start at either 50 mm (A and C) or 0 mm
(B and D) from the semen/CVM interface. Paths were chosen so that the
passage time was within one standard deviation of the expected mean pas-
sage time (a ¼ 1). The a ¼ 0.9 path is derived from the same realization as
for a ¼ 1, with the modification that a virion in the CVM has a probability
an of free diffusion.




FIGURE 3 HIV concentration profiles across genital secretions coating
the vaginal epithelium for (A) a ¼ 1, (B) a ¼ 0.95, (C) a ¼ 0.9, and (D)
a ¼ 0.8, at an initial NIH45-46 concentration of 5 mg/mL. The virus con-
centration curves are shown at 0, 40, 80, and 120 min. (E and F) Percentage
2032 Chen et al.trapped (Fig. 2 D). In both cases, the number of HIV-bound
NIH45-46 effectively suppresses the probability that any
HIV/NIH45-46 complex can be simultaneously free of all
potential IgG-mucin interactions for extended periods of
time. This in turn leads to rapid and sustained sequestration
of viruses in CVM despite the extremely weak affinity of
each IgG-mucin bond (Fig. 2, C and D, and see the Support-
ing Material for Fig. S1 A, inset). Because of the fast time-
scale of the Ab-mucin affinities relative to that of virion
diffusion across the CVM, we obtain nearly identical results
whether modeling virion-bound Ab-mucin interactions as
preventing the motion of the Ab-virion complex for an an
fraction of time or by utilizing an average-reduced (by an)
diffusion coefficient.
We further analyze the mean number of bound NIH45-46
Ab on HIV virions that possess the following characteris-
tics: 1. Remain in semen, 2. Remain in CVM, or 3. Penetrate
across the CVM layer and reach the vaginal epithelium. Not
surprisingly, virions that successfully penetrated CVM have
a markedly lower number of NIH45-46 molecules bound to
them (see Fig. S1 B; ~3–5-fold lower). Interestingly, virions
sequestered in CVM possess a somewhat greater number of
NIH45-46 molecules bound than virions that remain in
semen; this likely reflects a combination of marginally
higher concentration of free NIH45-46 in CVM than in
semen, and the retarded mobility of HIV/NIH45-46 com-
plexes in CVM.of virus in CVM within 1 and 5 mm, respectively, of the semen/CVM inter-
face over time.
HIV-specific IgG in CVM induces rapid formation
and pinning of an HIV concentration front near the
semen/CVM interface
We next evaluate how small changes in a influence viral
flux and spatial distribution within the CVM layer. Interest-
ingly, rather than a uniform distribution of virions
throughout the CVM layer, the model suggests HIV-bind-
ing IgG quickly induces formation of a stationary virion
concentration front, with HIV virions concentrated in
a thin CVM layer close to the semen/CVM interface
(Fig. 3, and see Movie S3 and Movie S4). An HIV concen-
tration front forms even when individual IgG-mucin
affinity is weak (Fig. 3, B and C, versus Fig. 3 A), and
becomes markedly more pronounced with further subtle
increases in IgG-mucin affinity (Fig. 3 D). The effective-
ness of this IgG-mediated molecular shield against HIV
diffusion is reflected by several features: the peak virus
concentration at the semen/CVM interface (Fig. 3 E); the
fast rate at which virions concentrate at the interface
(Fig. 3 E); and the fraction of virions becoming trapped
within the first 5 mm from the semen/CVM interface
(Fig. 3 F). Indeed, even at the weakest affinity simulated
(a ¼ 0.95), we observe a >30% drop in flux of HIV virions
arriving at the vaginal epithelium after 2 h (Fig. 4, A–D).
The flux of HIV virions reaching target cells can be
reduced by >90% if the IgG-mucin affinity is slightlyBiophysical Journal 106(9) 2028–2036stronger (a ¼ 0.8), or if the NIH45-46 concentration is
further increased (Fig. 4 E).IgG-mediated trapping enhances protection by
neutralizing antibodies
It is unclear the extent to which reducing the flux of HIV
virions to the vaginal epithelium can improve protection
naturally afforded by broadly neutralizing antibodies.
Conceptually, virion trapping in CVM enhances protection
by neutralizing antibodies only if trapping directly reduces
the flux of virions with substantial amounts of infectious
(i.e., Ab-free) Env spikes; trapping does not enhance protec-
tion against virions that are already completely neutralized at
the time of cellular encounters. The latter is particularly true
for virions with few Env spikes natively, which may not
generate sufficient IgG-mucin avidity to become trapped in
mucus yet only require a small number of bound Ab to
become effectively neutralized. Nevertheless, it is likely
difficult to neutralize all Env spikes on HIV virions, espe-
cially on virions that have relatively more Env spikes and/
or quickly traverse the mucus layer and reach target cells.
In these instances, which may represent the majority of the
virions responsible for vaginalHIV transmission, the reduced
A B C D
E F G
FIGURE 4 (A–D) Percentage of viral load in semen, CVM, and cells over time for (A) a ¼ 1, (B) a ¼ 0.95, (C) a¼ 0.9, and (D) a ¼ 0.8 and an initial Ab
concentration of [NIH45-46]¼ 5 mg/mL. (E) Percent of viral load arriving at epithelium in 2 h for various values of a, initial Ab concentration [NIH45-46].
(F) HIV infectivity (defined as the fraction of Ab-free Env spikes on virions arriving at the epithelium compared with [NIH45-46] ¼ 0 mg/mL, a ¼ 1) for
various a, initial Ab concentration [NIH45-46]. (G) Predicted IC50, IC80 (see Table 1), [NIH45-46] ¼ 5 mg/mL.
Modeling the IgG-Mucin Barrier to HIV 2033flux due to trapping viruses by IgG-mucin interactions
may markedly enhance protection. We thus seek to quan-
tify protection by Ab-neutralization without IgG-mucin
affinity (a¼ 1) as well as with varying degrees of Ab-mucin
affinity.
It is generally assumed that the binding of a single IgG
molecule to an Env spike is sufficient to inactivate the infec-
tivity associated with that spike, and that each additional
bound IgG to a previously IgG-free Env incrementally re-
duces the likelihood of infection (45–47). By modeling the
number of IgG-free and IgG-bound Env onvirions that arrive
at the vaginal epithelium compared to IgG-null control, we
can estimate any improved protection (reduction in infec-
tivity) afforded by IgG-mediated trapping of HIV. Our
model suggests that NIH45-46, with mucin affinity in the
a¼ 0.8–0.95 range, can substantially improve the protective
efficacy of NIH45-46 by neutralization alone, especially at
higher NIH45-46 concentrations (Fig. 4, F and G). These
results strongly underscore the importance of harnessing
IgG-mucin interactions in the context of vaccine and pro-
phylactic antibody development.DISCUSSION
During sexual transmission, pathogens are first exposed to
CVM coating the female reproductive tract, and viruses
and obligate intracellular bacteria (e.g., Chlamydia) must
penetrate CVM to reach target cells in the vaginal epithe-
lium or submucosa. Thus, an effective CVM barrier should
exclude and eliminate pathogens directly at the portal ofentry. Unfortunately, pathogens have evolved numerous
mechanisms to quickly penetrate across mucus, such as sur-
faces that evade adhesive interactions with sticky mucins,
and/or by evolving directed motility apparatus (e.g., beating
flagella). Indeed, many pathogens that readily infect
mucosal surfaces, including HIV, HSV, Norwalk virus,
and Human Papillomavirus (HPV), have all been shown to
readily penetrate human mucus secretions (14,22,23). IgG-
mucin interactions that trap pathogens in mucus therefore
represent an attractive and potentially important mechanism
by which the immune system can readily adapt and rein-
force the body’s first line of defense against diverse and
rapidly evolving pathogens. Trapping virions in genital tract
mucus may markedly reduce heterosexual transmission of
viral infections. Women acquire many of the major sexually
transmitted viral infections (e.g., HIV, HPV, and HSV) at
rates of ~1 per 100–1000 sex acts on average (48–52), sug-
gesting that few, if any, of these infectious virions are able to
infect target cells per intercourse. Consequently, any reduc-
tion in the flux of virions that reach target cells should pro-
portionally reduce transmission rates. Blocking infections
directly at the portal of entry may be especially important
against infections that are difficult if not impossible to
cure, including HIV, Herpes, and other polymicrobial infec-
tions (e.g., bacterial vaginosis).
Due to the inability to detect permanent, high-affinity
bonds between individual Ab molecules and mucins, the
notion that Ab can work in tandem with mucus to block in-
fections has received little attention to date. Surprisingly,
our model suggests that even exceedingly weak IgG-mucinBiophysical Journal 106(9) 2028–2036
2034 Chen et al.interactions are capable of rapidly inducing a concentration-
front formation of highly concentrated virions at the semen/
CVM interface. This concentration front formation is likely
critically dependent on the ability of IgG to undergo rapid
diffusion in genital secretions. Because HIV virions are
uniformly distributed within seminal fluids, and there is sub-
stantially greater volume of semen than CVM, the majority
of virions in semen are actually located at substantial dis-
tances away from the semen/CVM interface just after semen
deposition. Because IgG possesses diffusivity nearly 30-fold
greater than that for HIV virions in genital secretions, they
can diffuse into semen much more quickly than HIV can
diffuse into CVM. Thus, HIV-specific IgGs such as
NIH45-46 likely accumulate on the virions in substantial
quantities before the HIV/NIH45-46 complexes enter the
CVM layer. As soon as they reach the CVM layer, HIV/
NIH45-46 complexes with a sufficient number of bound
NIH45-46s experience a dramatic downshift in their diffu-
sivity, as captured by the diffusion coefficient Dvn, and
finally become immobilized near the semen/CVM interface
by a sufficient number (n) of IgG-mucin bonds. Mucus is a
non-Newtonian fluid that is continuously secreted and shed;
in this process, the most superficial mucus layers and semen
should be cleared much more quickly than mucus immedi-
ately adjacent to the epithelium (35). Indeed, seminal
discharge is typically observed flowing out of the introitus
within minutes of ejaculation. Thus, the formation of a
virion concentration front at the semen/CVM interface—
the maximum distance away from the vaginal epithe-
lium—not only should minimize the flux of virions reaching
target cells in the submucosa, but also likely enable most
rapid elimination of viruses by natural mucus clearance
mechanisms.
Despite evidence that IgG can trap both viruses and
highly motile bacteria with remarkable potency, the actual
biophysical mechanism underscoring this muco-trapping
phenomenon remains not well understood. Indeed, it was
unclear whether the exceedingly weak affinity of each
IgG-mucin crosslink (a ¼ 0.8–0.95 range, as suggested
in the literature (14,17,19)) can collectively produce suffi-
cient avidity to trap HIV virions, or if HIV could only be
immobilized by individually high affinity and stable IgG-
mucin bonds, as suggested in Fahrbach et al. (42). There
are a number of factors that may potentially alter IgG-
mucin affinity, including variations in the N-glycans on
IgG-Fc (19). High-affinity bonds between individual path-
ogen-bound IgG and mucins are also conceptually possible
if a conformational change in the Fc domain of IgG upon
binding to antigen targets can expose a moiety with sub-
stantially greater muco-affinity than native, unbound IgG.
Because this question is difficult to directly address exper-
imentally, we developed our mathematical model and
simulation to explore HIV diffusional dynamics incorpo-
rating known antibody binding kinetics and IgG-mucin
affinity. Although our findings do not disprove the possibil-Biophysical Journal 106(9) 2028–2036ity of antigen-binding-induced increase in muco-affinity of
IgG, we clearly demonstrate that very weak IgG-mucin
interactions alone can theoretically generate sufficient
avidity to immobilize HIV and likely other sexually trans-
mitted viruses in CVM.
In our model with NIH45-46, one of the most potent
broadly neutralizing IgGs against HIV, trapping viruses in
CVM appears to only modestly improve protection
compared with neutralization. Nevertheless, trapping vi-
rions in mucus can likely play a greater role in protection
afforded by other less potently neutralizing IgGs. This
includes IgGs that readily bind virions but are not neutral-
izing or even IgGs that bind relatively weakly to HIV,
because trapping virions in mucus require only binding
and not necessarily neutralizing IgG. Nonneutralizing IgG
are commonly found in nature; indeed, many of the natu-
rally produced IgG against HIV found in HIVþ patients
associate with either the lipid membrane of HIV virions,
or other parts of the gp120 site on the Env spike not directly
involved in HIV infection of immune cells (53). Likewise,
virtually all of the IgGs detected in the moderately success-
ful RV144 trial were nonneutralizing, and thus must depend
on other immune protective mechanisms to block HIV
transmission. In line with this hypothesis, we recently found
that a nonneutralizing monoclonal IgG against HSV is able
to mediate substantial vaginal protection in mice, but the
protection is abolished in the absence of an intact mucus
layer (19). Efforts to harness IgG-mucin interactions for
improved mucosal protection, by maximizing virion-bind-
ing IgG, may further increase the repertoire of antigen sites
that can be utilized for vaccine or prophylaxis development.
Our model is only a first step toward an improved quan-
titative understanding of the dynamics of mucosal immunity
in the female reproductive tract. We expect additional itera-
tions, and future improvements to our model will provide
further predictive insights into reinforcing vaginal mucosal
immunity against HIV and other sexually transmitted
infections.SUPPORTING MATERIAL
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